Site is Being Upgraded

Lifespan extension therapy:  D-3-Hydroxy Butyrate (3HB) increases life span via up-regulation of its target gene BubR1, 4/February/2018, 11.42 pm

Molecular therapy for CyclinD3-CDK6 overexpressing cancers: Roscovitine, a cyclin kinase-dependent inhibitor,  inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down regulation of its target gene, 4/February/2018, 11.32pm
February 4, 2018
Molecular therapy for glioblastoma: A therapeutic mix encompassing Macbecin, Temozolomide, EGCG, Salinomycin, Fluvastatin and Chloroquine (MTESF) inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 4/February/2018, 11.57 pm
February 4, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy:  D-3-Hydroxy Butyrate (3HB) increases life span via up-regulation of its target gene BubR1


What is known? 

D-3-Hydroxy Butyrate (3HB) has been shown to extend murine lifespan. However, the exact mechanism of action is far from clear.


From research findings to Therapeutic Opportunity: 

This study suggests, for the first time, that D-3-Hydroxy Butyrate (3HB)by increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. A therapeutic mix encompassing D-3-Hydroxy Butyrate (3HB) may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. The chemical structure of D-3-Hydroxy Butyrate (3HB)

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “D-3-Hydroxy Butyrate (3HB)  or its analogues, either alone or in combination with other drugs may be used to extend the lifespan of an individual (fig. 2).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing D-3-Hydroxy Butyrate (3HB) increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy:  D-3-Hydroxy Butyrate (3HB) increases life span via up-regulation of its target gene BubR1, 4/February/2018, 11.41 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.